NasdaqGM:TVTXBiotechs
Travere Therapeutics (TVTX) Heads Into Q1 2026 With Sharply Narrowed Trailing Losses Testing Bull Case
Q1 2026 earnings snapshot sets up margins story for Travere Therapeutics (TVTX)
Travere Therapeutics (TVTX) heads into its Q1 2026 update with recent quarterly revenue of US$129.7 million in Q4 2025 and basic EPS of US$0.29 in Q3 2025 giving way to a loss of US$0.24 per share in Q4, alongside trailing 12 month revenue of US$490.7 million and a net loss of US$50.3 million. Over the past year, revenue has moved from US$233.2 million on a trailing 12 month basis in Q4 2024 to US$490.7 million in...